-+ 0.00%
-+ 0.00%
-+ 0.00%

Revive Therapeutics releases investor presentation on bucillamine biodefense program

PUBT·08/28/2026 13:59:28
Listen to the news
Revive Therapeutics releases investor presentation on bucillamine biodefense program
  • Revive Therapeutics released its Q3 2026 investor presentation, centering on bucillamine for government biodefense and pandemic-preparedness procurement.
  • DRDC animal-model data reported bucillamine matched NAC on a brain receptor endpoint, with no lung hemorrhage versus hemorrhage in NAC.
  • Confirmatory DRDC studies are set to start in Q4 2026, targeting brain injury, oxidative stress, respiratory function.
  • Capital snapshot cited share price C$ 0.03, market cap about C$ 13 million, common shares 435,684,000, warrants 63,317,263.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revive Therapeutics Ltd. published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.